Cargando…
Effects of glucagon‐like peptide‐1 receptor agonists on kidney function and safety in type 2 diabetes patients
Glucagon‐like peptide‐1 receptor agonists have been recommended in diabetic kidney disease patients.[Image: see text]
Autores principales: | Kim, Min Kyung, Kim, Doo‐Man |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169368/ https://www.ncbi.nlm.nih.gov/pubmed/33759351 http://dx.doi.org/10.1111/jdi.13552 |
Ejemplares similares
-
Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012) -
Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017) -
Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022) -
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)